Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02540876 · ClinicalTrials.gov registry record · Phase 1
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
A Phase 1 study of Metastatic Malignant Neoplasm and Solid Neoplasm, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT02540876: Completed Phase 1 study of Metastatic Malignant Neoplasm and Solid Neoplasm, sponsored by University of Chicago.
NCT02540876 is a Phase 1 study of Metastatic Malignant Neoplasm and Solid Neoplasm that has completed, run by University of Chicago. The registered enrollment target is 12 participants, below the 338-participant average among 15 other Metastatic Malignant Neoplasm trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02540876, a Phase 1 study of Metastatic Malignant Neoplasm and Solid Neoplasm, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot phase I trial studies how well ilorasertib works in treating patients with cyclin-dependent kinase inhibitor 2A (CDKN2A)-deficient solid cancers that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or have spread to other places in the body (metastatic) and cannot be removed by surgery. Ilorasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Change in tumor measurements from baselines through end of study.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Ilorasertib
Study Locations (1)
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-09-08 |
| Est. Completion | 2019-02-08 |
| Phase | Phase 1 |
What the finished NCT02540876 record still lists
NCT02540876 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 338-participant average among 15 other Metastatic Malignant Neoplasm trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Metastatic Malignant Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02540876 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT02540876 about?
NCT02540876 is a clinical study titled "Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery". This pilot phase I trial studies how well ilorasertib works in treating patients with cyclin-dependent kinase inhibitor 2A (CDKN2A)-deficient solid cancers that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or have spread to other places ...
What is the current status of trial NCT02540876?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-09-08. Estimated completion is 2019-02-08.
What conditions does trial NCT02540876 study?
This clinical trial studies the following conditions: Metastatic Malignant Neoplasm, Solid Neoplasm, Unresectable Malignant Neoplasm.
What interventions are being tested in trial NCT02540876?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Ilorasertib (DRUG).
Who is sponsoring clinical trial NCT02540876?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02540876 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02540876's enrollment target sits among peer trials
12 16th of 15 the lowest of 15 other Metastatic Malignant Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Malignant Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
RECRUITING · Phase 1
-
Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer
RECRUITING · Phase 2
-
Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center
ACTIVE NOT RECRUITING · NA
-
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)
ACTIVE NOT RECRUITING · Phase 2
-
Cryoablation for the Treatment of Metastatic Cancer
ACTIVE NOT RECRUITING · NA
-
A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI